Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 2005

View Archived Issues

NIH accepts clinical study of Zestra

CombinatoRx and HenKan sign Asian agreement for CRx-026

Alexza Molecular Delivery changes name to Alexza Pharmaceuticals

Clinical evidence confirms the survival benefits of Provenge in advanced prostate cancer

ARIES-2 study of ambrisentan completes enrollment

ACT 3 atrial fibrillation study of RSD-1235 completes enrollment

Pivotal study of MBP-8298 expands into Europe

FDA requests information on phase II study of arimoclomol for ALS

Schwarz Pharma acquires remaining rights to rotigotine

Kirin Brewery acquires Hematech

XL-820 enters phase I study in solid tumors

ONO-4128 begins phase III trials in treatment-experienced HIV patients

Schering-Plough to acquire from Millennium exclusive U.S. Integrilin rights

Progress in NicOx ophthalmology collaboration with Pfizer

IGN-311 begins new study, subject of new Asian licensing agreement

M-2000: a novel, safe and efficacious NSAID for arthritis

Wockhardt reports successful progression of new quinolone into clinical trials

MC4 receptor agonist shows in vivo efficacy for obesity and sexual dysfunction

In vitro and in vivo effects of novel DPP-IV inhibitor KR-62436

NITD to test Alfacell's AC 03-636 for Dengue fever

FDA issues public health advisory for mifepristone

New agents for treating hepatitis C infection disclosed

Recent Sumitomo patent reports new treatments for skin and allergic diseases

Update on the antitumor efficacy and safety of pemetrexed

New clinical data on the survival effects of bexarotene in advanced NSCLC

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...